

Un-audited Financial Results for the Quarter ended 31.12.2009 (Rs. in Lacs)

S No.	PARTICULARS	Quarter ended	Quarter ended	9 Months Ended	9 Months Ended	Year Ended
		31.12.2009	31.12.2008	31.12.2009	31.12.2008	31.3.2009
		Un-audited	Un-audited	Un-audited	Un-audited	Audited
1.	Gross Sales/Income from Operations	27259.20	14416.72	74039.20	59727.33	77997.65
	Less : Excise Duty	1281.05	985.63	3506.24	4159.60	5200.85
	Net Sales / Income from Operations	25978.15	13431.09	70532.96	55567.73	72796.80
	Other Operating Income	75.00	38.28	210.00	216.09	314.33
	Total Operating Income	26053.15	13469.37	70742.96	55783.82	73111.13
2.	Expenditure					
	a. (Increase)/decrease in stock in trade	104.78	(721.56)	843.53	(1181.17)	(734.24)
	b. Consumption of Raw Material	17789.80	9170.86	47289.63	38716.53	49332.78
	c. Employees Cost	820.44	784.41	2395.36	2119.46	2772.50
	d. Depreciation	1013.71	837.78	2928.73	2303.50	3018.86
	e. Other Expenditure	1813.95	1624.81	5268.62	4966.86	7476.21
	Total Expenditure	21542.68	11696.30	58725.87	46925.18	61866.11
3.	Profit from Operations before Other Income, Interest & Exceptional Items (1-2)	4510.47	1773.07	12017.09	8858.64	11245.02
4.	Other Income	57.64	129.30	208.05	201.40	292.23
5.	Profit before Interest & Exceptional Items (3+4)	4568.11	1902.37	12225.14	9060.04	11537.25
6.	Interest	1353.41	1333.15	4056.33	3351.70	4960.55
7.	Profit after Interest but before Exceptional Items (5-6)	3214.70	569.22	8168.81	5708.34	6576.70
8.	Exceptional Items					
9.	Profit from ordinary activities before tax (7+8)	3214.70	569.22	8168.81	5708.34	6576.70
10.	Tax Expenses					
	Current Tax	546.34	64.49	1388.29	646.75	744.91
	Fringe Benefit Tax		4.00		12.00	23.00
	Mat Credit Entitlement	(546.34)	(64.49)	(1388.29)	(646.75)	(612.92)
	Deferred tax					980.55
	Excess Provision for taxation written back					(16.66)
11.	Net Profit from ordinary activities after tax (9-10)	3214.70	565.22	8168.81	5696.34	5457.82
12.	Extraordinary Item (net of tax expense)					
13.	Net Profit for the period (11-12)	3214.70	565.22	8168.81	5696.34	5457.82
14.	Paid up Equity Share Capital (Face Value per share : Re. 1/-)	1522.61	1522.61	1522.61	1522.61	1522.61
15.	Reserves excluding Revaluation Reserves					28789.97
16.	Earnings per Share (EPS)					
	Basic EPS before Extraordinary items	2.11	0.37	5.37	3.74	3.57
	Diluted EPS before Extraordinary items	1.54	0.27	3.90	2.73	2.60
	Basic EPS after Extraordinary items	2.11	0.37	5.37	3.74	3.57
	Diluted EPS after Extraordinary items	1.54	0.27	3.90	2.73	2.60
17.	Public Shareholding					
	- Number of Shares	54119330	54119330	54119330	54119330	54119330
	- Percentage of Shareholding	35.54	35.54	35.54	35.54	35.54
18.	Promoters and Promoter Group Shareholding					
	a) Pledged/Encumbered					
	- Number of Shares	0	N.A.	0	N.A.	0
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	0.00	N.A.	0.00	N.A.	0.00
	- Percentage of Shares (as a % of the total share capital of the company)	0.00	N.A.	0.00	N.A.	0.00
	b) Non-encumbered					
	- Number of Shares	98141640	N.A.	98141640	N.A.	98141640
	- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00	N.A.	100.00	N.A.	100.00
	- Percentage of Shares (as a % of the total share capital of the company)	64.46	N.A.	64.46	N.A.	64.46

Notes:

- The Company has entered the regulated market of API by adding a major MNC in western Europe as its customer. The Company expects to add more clients in the regulated market in the near future.
- The Total Operating Income & Profit of the company has increased by 93% & 465% respectively over the corresponding quarter of previous year.
- The above financial results were reviewed by Audit Committee on 12.01.10 and approved by the Board in its meeting held on even date i.e. 12.01.10
- The above financial results are on stand alone basis.
- The company is exclusively in the pharmaceutical business segment.
- Provision for Deferred Tax liability would be made in the Audited Financial Results for the year ending March 31, 2010.
- Status of Complaints: a) Pending at the beginning of Quarter - Nil b) Received During the Quarter - 4
c) Disposed Off During the Quarter - 4 d) Pending at the end of Quarter - Nil

**By Order of the Board of Directors
of Nectar Lifesciences Limited
Sd/-**

(Sanjiv Goyal)

Chairman & Managing Director

Dated : 12.01.2010

Place : Chandigarh